Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9

A clinical-stage immune-oncology company, Forty Seven, Inc., that works to develop therapies targeting cancer immune evasion pathways, has revealed clinical data from Phase 1b/2. The company is evaluating a new drug combination of Recombinant Human Anti-CD47 Antibody, 5F9 and rituximab to treat relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), comprising indolent lymphoma and diffuse large B-cell lymphoma (DLBCL).

According to sources, Leukemia and Lymphoma Society(LLS) has funded the Phase 1b/2 program of immuno-oncology company via Therapy Acceleration Program® (TAP). The patients who have failed to receive standard-of-care therapies to treat r/r B-cell NHL have undergone the 5F9 clinical trial combined with rituximab.

As per updated clinical data, patients had been treated with different types of dose alternations depending on the target level. More precisely, all patients obtained a 1mg/kg initial dose of 5F9 to alleviate on-target anemia. Around 10 to 45 mg/kg of 5F9 doses had been given to patients in the Phase 1b trial and 30 or 45 mg/kg had been given to the patients in the phase 2 trial.

The report claims, till May 2019, nearly 115 patients had received treatment from the Phase 1b/2 trial – around 70 DLBCL patients, 41 follicular lymphoma (FL) patients, and 4 marginal zone lymphoma (MZL) patients. Those who were treated with 5F9 for nearly 24 months did not observe autoimmune-related adverse events (AE) and late safety signals.

Post the announcement, Forty Seven’s Chief Medical Officer, Chris Takimoto stated that the company was rather satisfied to witness meaningful activity in the newly-defined population that has apparently never before been evaluated in clinical trials. He further added that these developments brought them closer to achieve their vision of making 5F9 as a cornerstone immunotherapy for the treatment of cancers.

Despite on-going clinical trial, Forty Seven, Inc is putting its efforts to develop 5F9 for the patients with DLBCL. In this regard, Forty Seven has collaborated not only with Acerta Pharma to evaluate triplet regimen of 5F9, acalabrutinib, and rituximab, but also with Genentech to evaluate regimen of 5F9, atezolizumab, and rituximab.

https://ir.fortyseveninc.com/news-releases/news-release-details/forty-seven-inc-announces-updated-data-phase-1b2-clinical-trial